Fabtech Technologies Limited (FTL) has issued an official statement to address market confusion regarding its corporate identity. The company has emphasized that it operates as a distinct entity from Fabtech Technologies Cleanrooms Limited (FTCL), with separate management structures and business strategies.

Key Points of Clarification

• Separate Entities: FTL and FTCL are independent, individually listed companies.
• Distinct Management: Each company operates under its own management team.
• Different Business Models: The companies have separate business strategies and focus areas.

Company Profiles

To further clarify the distinction between the two entities, here's a comparison of their key characteristics:

Importance of the Clarification

This clarification is crucial for investors and stakeholders to understand the distinct nature of these two companies. While both share the Fabtech legacy, they operate in different market segments and have unique business models. This distinction is important for accurate market analysis, investment decisions, and understanding each company's potential and risks.

FTL's Executive Director, Hemant Mohan Anavkar, signed the official press release, underlining the company's commitment to transparency and clear communication with its stakeholders. This proactive approach to addressing potential market confusion demonstrates FTL's dedication to maintaining investor trust and ensuring accurate representation in the financial markets.

Investors and market participants are advised to take note of this clarification when considering their investment strategies or analyzing these companies. It's essential to recognize the separate identities, operations, and market positions of Fabtech Technologies Limited and Fabtech Technologies Cleanrooms Limited to make informed decisions.

As both companies continue to operate in their respective domains, this clarification serves as a reminder of the importance of due diligence and accurate information in the complex landscape of corporate identities and market listings.

Fabtech Technologies Limited , a global turnkey engineering solutions provider for the pharmaceutical, healthcare, and biotech sectors, has reported strong financial results for the first half of fiscal year 2026. The company's performance highlights its growing presence in pharmaceutical emerging markets and its focus on enabling medicinal independence across various regions.

Financial Highlights

• Total income reached INR 19,322.80 lakhs, marking a substantial year-on-year growth of 109.9%
• Net profit stood at INR 2,198.02 lakhs, up 101.6% compared to the same period last year
• EBITDA improved to INR 2,839.99 lakhs, with margins expanding to 14.7%

Strong Order Book and Market Presence

Fabtech Technologies maintains a robust order book of INR 90,441.87 lakhs as of July 31, 2025, providing clear visibility for sustained revenue momentum in the coming quarters. The company has reported a 7-9% growth in its order book from July to September 2025, indicating continued market traction.

Global Expansion and Project Execution

• Operating across 22 countries, with a focus on MENA, GCC, and ECO Zone regions
• Secured several high-value turnkey projects in markets investing in pharmaceutical self-reliance and healthcare infrastructure
• Average project execution timeline of 18-24 months, from concept and design to complete supply chain and execution

Business Model and Capabilities

Fabtech Technologies offers end-to-end turnkey solutions for pharmaceutical and biotech manufacturing setups, focusing on three critical pillars:

1. Process systems
2. Air management
3. Water purification and distribution

The company's asset-light model, supported by in-house manufacturing capabilities, enhances execution agility and scalability while maintaining cost efficiency. Approximately 30% of the products supplied in turnkey projects are manufactured in-house.

Market Outlook and Strategy

Ashwani Kumar Singh, Chief Executive Officer of Fabtech Technologies, commented on the company's performance and outlook: "The first half of FY '26 has been a period of strong growth and strategic progress for the company. We continue to build on our execution excellence, expand our presence across key international markets, and strengthen our leadership as a global turnkey engineering solution provider to the life science and healthcare sector."

The company remains focused on strengthening its global footprint, deepening its presence in high-growth regions, and driving sustainable profitability. Fabtech Technologies is committed to building long-term relationships with clients by consistently delivering quality, reliability, and compliance across all projects.

As pharmaceutical emerging markets move towards medicinal independence, Fabtech Technologies is well-positioned to capitalize on the growing demand for end-to-end turnkey solutions in the life sciences sector.

Looking Ahead

While the company does not provide specific quarterly guidance due to the project-based nature of its business, management expressed confidence in sustaining growth and improving upon previous year's performance. Fabtech Technologies aims to maintain its focus on operational efficiency, strategic partnerships, and technology-led innovation to drive long-term value creation for its stakeholders.